Allogeneic BMT remains the only curative treatment for major b-thalassemia.
1,2 Early graft failure and persistent mixed chimerism are not uncommon after BMT, 3 but late recurrence of b-thalassemia is rare, with only a few cases having been treated successfully with a second transplant. 4, 5 Although donor lymphocyte infusion (DLI) is an effective treatment for late recurrence of some hematological malignancies after allogeneic BMT, 6 DLI has only been reported in few cases for early graft failure in thalassemia. 7, 8 We report a case of late recurrent b-thalassemia major successfully treated with DLI 23 years after BMT. The patient signed institutional review board-approved consent to allow his medical records to be used for research. A 2.5-year-old boy received BMT from his HLA-identical ABO-mismatched sister with b-thalassemia minor after conditioning with BU (14 mg/kg) and CY (200 mg/kg). Pretransplant Lucarelli's risk category was class 2. Cyclosporine and methotrexate were used for GVHD prophylaxis. Trilineage engraftment was achieved by day 36, with full donor chimerism documented by cytogenetic analysis on day 726 after BMT. He developed no acute or chronic GVHD and had cyclosporine discontinued on day 82 after BMT.
The patient did well with normal development and adequate blood cell counts until 22.4 years after BMT, when he presented with an acute episode of dyspnea, fever and hemolytic anemia. His hemoglobin level was 5.5 g/dL, but WBC and platelet counts were normal. He received 2 U of irradiated RBCs and hemolysis improved spontaneously. Seven months later hemolytic anemia was noted again and he became dependent on RBC transfusion. Hb electrophoresis revealed recurrence of b-thalassemia major with increased Hb F (23.5%), decreased Hb A1 (73.7%) and normal Hb A2 (2.8%). The BM was hypercellular with erythroid hyperplasia, and with no evidence of dysplasia, blasts or cytogenetic abnormalities. Chimerism tests revealed 10% of unfractionated BM cells, 5.5% of pancytopenia 33 days after DLI. GVHD resolved with prednisone (2 mg/kg) and tacrolimus treatment. Granulocytopenia resolved after 1 week of G-CSF administration. Donor chimerism of CD3 þ and CD33 þ cells in peripheral blood increased and eventually reached 100% by day 70 after DLI. A rapid increase in Hb was noted as early as day 42 after DLI along with normalization of all other blood cell counts. The patient developed no infections requiring antibiotics and has remained transfusion independent since day 36 after DLI. Quiescent onset NIH overlap syndrome of the mouth, liver and gut was diagnosed on day 293 after DLI, which responded well to reinstitution of prednisone (1 mg/kg) followed by a taper to 0.5 mg/kg every other day and tacrolimus.
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þ fractionated marrow cells, 78% of peripheral blood CD3 þ cells and 2.6% of peripheral blood CD33 þ cells to be of donor origin. After consideration of chronic transfusion with chelation, second transplant or DLI, the patient elected to pursue treatment with DLI. The donor had a history of two prior pregnancies and had just delivered her second son 3 weeks before the apheresis of lymphocytes for DLI. The patient received DLI at a dose of 3 Â 10 7 CD3 þ cells/ kg without any other prior therapy or GVHD prophylaxis. Infection was not present at DLI. His clinical course after DLI is detailed in Figure 1 . As shown, he developed neutropenia requiring G-CSF administration for a few days and GVHD responding to prednisone and tacrolimus. Subsequently he achieved complete recovery of his blood cell counts with return of 100% donor chimerism. The patient is transfusion-independent, has mild chronic GVHD of the mouth and a Karnofsky score of 90% at his last contact at 1 year after DLI.
To the best of our knowledge, this is the longest interval from transplant to recurrence of b-thalassemia after BMT from an HLA-identical sibling. The complete recovery of hematopoiesis of donor origin by DLI represents direct evidence of a graft-versus-thalassemia effect and, moreover, of the renewal capacity of the residual donor hematopoietic stem cells, which reconstituted the patient's marrow and proliferated normally more than two decades after transplantation. 9 DLI may represent an alternative intervention for late recurrence of b-thalassemia after BMT.
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